Category : Healthcare | Published Date : Nov 2024 | Type : Press Release
In the newly published report, Consegic Business Intelligence states that the Acromegaly Market size was valued at USD 1.48 Billion in 2023 and is projected to reach USD 2.51 Billion by 2031, growing at a CAGR of 6.8% from 2024 to 2031. Acromegaly is a rare hormonal disorder caused by excessive growth hormone production, often due to a benign pituitary tumor. This condition leads to abnormal bone and tissue growth, particularly in the hands, feet, and face, and can lead to severe health issues if untreated. Treatment typically includes surgery, medications, or radiation, with hospitals, endocrinology clinics, and research institutions serving as primary end-users.
The report comprises the Acromegaly Market Share, Size & Industry Analysis, By Drug Type (Somatostatin Analogs, Dopamine Agonists, Growth Hormone Receptor Antagonists (GHRAs), Others), By Treatment (Medications, Surgery, Radiation Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024-2031.
The report contains detailed information on Acromegaly Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Advancements in diagnostic technologies enabling early intervention are propelling market growth, while high treatment costs and limited access to therapies may hinder expansion.
By drug type, the market is segmented into somatostatin analogs, dopamine agonists, GHRAs, and others.
By treatment, the market is segmented into medications, surgery, and radiation therapy.
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Report Attributes | Report Details |
Study Timeline | 2018-2031 |
Market Size in 2031 | USD 2.51 Billion |
CAGR (2024-2031) | 6.8% |
By Drug Type | Somatostatin Analogs, Dopamine Agonists, Growth Hormone Receptor Antagonists (GHRAs), Others |
By Treatment | Medications, Surgery, Radiation Therapy |
By Distribution Channel | Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies |
By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
The acromegaly market is competitive, with major players focused on R&D and clinical trials to expand treatment options.
List of prominent players in the Acromegaly Industry: